Multiple Myeloma

Nina Shah, MD, discusses the future of CAR T-cell therapy in multiple myeloma. 

Thomas G. Martin, MD, discusses the safety profile of belantamab mafodotin-blmf in relapsed/refractory multiple myeloma.

Betsy O'Donnell, MD, discusses ongoing research efforts in multiple myeloma.

A new subcutaneous formulation, daratumumab and hyaluronidase-fihj, provides similar efficacy in a more convenient and efficient regimen that is likely to change practice.

Noopur S. Raje, MD, discusses recent findings with melflufen in relapsed/refractory multiple myeloma.

Luciano J. Costa, MD, PhD, discusses unmet need​s in relapsed/refractory multiple myeloma. 

Sagar Lonial, MD, FACP, discusses the FDA approval of belantamab mafodotin in patients with relapsed/refractory multiple myeloma.

The FDA has approved belantamab mafodotin-blmf (Blenrep) as a treatment for patients with relapsed/refractory multiple myeloma who have received 4 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.

Noopur S. Raje, MD, discusses remaining questions in multiple myeloma. 

Shaji K. Kumar, MD, discusses treatment discontinuation in the phase 3 ENDURANCE trial in newly diagnosed multiple myeloma.

Saad ​Z. Usmani, MD, FACP, discusses the key takeaways from the randomized phase 2 SWOG 1211 trial in patients with newly diagnosed, high-risk multiple myeloma.

Subcutaneous daratumumab in combination with pomalidomide and dexamethasone showed an improvement in progression-free survival versus pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma.

A biologics license application has been submitted to the FDA for idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma.

Noopur S. Raje, MD, discusses the quadruplet therapies that are currently available for patients with multiple myeloma.

Patients with smoldering myeloma whose disease harbors select genetic abnormalities may be an indicator that they could be at a higher risk for developing multiple myeloma.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for belantamab mafodotin as a monotherapy in the treatment of adult patients with multiple myeloma who have received at least 4 prior therapies and whose disease is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and aCD38-directed monoclonal antibody.

A triplet regimen comprised of selinexor, daratumumab, and dexamethasone proved to be highly active, inducing deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.

Noopur S. Raje, MD, discusses some of the most noteworthy research presented at the 2020 ASCO Virtual Scientific Program and the 2020 European Hematology Association Congress in multiple myeloma.

The Multiple Myeloma Research Foundation CureCloud® is a first-of-its-kind research initiative, developed to help arm researchers with the information they need to accelerate development of novel therapeutic strategies, provide a precision medicine approach to help inform providers’ and patients’ treatment decisions, and ultimately, find a cure for multiple myeloma.